Biotie Therapies - Decisions of general meeting

Resolutions of the Annual General Meeting of Biotie Therapies Corp. held on 28 March 2007

BIOTIE THERAPIES CORP.         STOCK EXCHANGE RELEASE
                               28 March, 2007


Resolutions of the Annual General Meeting of Biotie Therapies Corp.
held on 28 March 2007

The Annual General Meeting of Biotie Therapies Corp. was held on 28
March 2007.

The General Meeting of Shareholders adopted the income statement and
balance sheet including the consolidated income statement and
balance sheet for the financial year 1 January 2006-31 December
2006. The General Meeting of Shareholders resolved pursuant to the
proposal of the Board of Directors that the loss of the financial
year, EUR 8,021,000, shall be transferred to the company's equity.

The General Meeting of Shareholders discharged the members of the
Board of Directors and the President and CEO from liability
concerning the financial year from 1 January-31 December 2006.

The number of the members of the Board of Directors was resolved to
be four. Juha Jouhki, Pauli Marttila, Riku Rautsola and Piet Serrure
were re-elected as the members of the Board of Directors. Janne
Rajalahti, Authorized Public Accountant, and PricewaterhouseCoopers
Oy, Authorized Public Accountants, were elected as auditors of
Biotie Therapies Corp.

At the organization meeting of the Board of Directors, convened
immediately after the Annual General Meeting, Juha Jouhki was
elected as the Chairman of the Board of Directors and Pauli Marttila
as the deputy chairman.

The General Meeting resolved pursuant to the proposal of the Board
of Directors to amend the Articles of Association to better
correspond to the Finnish Companies Act entered into force on 1
September 2006. The Meeting resolved on the following amendments:

a) Removal of regulations concerning the amount and range of the
   share capital (Article 4).
b) Removal of the statement regarding the tasks of the Board of
   Directors in the management of the company and the statement 
   that a quorum requires the attendance of either the Chairman 
   or the Vice Chairman (Article 5).
c) Removal of the description of the President and CEO's function
   (Article 6).
d) The right to sign for the company was changed to the right of
   representation as set forth in the Finnish Companies Act 
   currently in force and removal of the statement how the Board 
   of Directors may grant rights to sign for the company.
   It is noted that the Company is represented by the Chairman of
   the Board of Directors and the Managing Director, each alone, 
   and two members of the Board of Directors together (Article 7).
e) Section which concerns the presentation of the financial
   statements at the Annual General Meeting of Shareholders was 
   amended so that the financial statements containing the 
   consolidated financial statements and the annual report, 
   which no longer is a part of the financial statements, will be
   presented at the meeting (Article 12).
f) The wording of the section concerning the adoption of the
   financial statements was amended so that according to it the 
   General Meeting of Shareholders shall adopt the financial 
   statements and the consolidated financial statements
   instead of the previous income statement and balance sheet and
   the consolidated income statement and balance sheet (Article 12).


The General Meeting resolved pursuant to the proposal of the Board
of Directors to amend the terms and conditions of the company's
convertible capital loan of 2004. Further, the General Meeting
resolved to amend the terms and conditions of the 2004 and 2006
option programmes. The references in terms of both the convertible
capital loan and option programmes to terms and practices under the
former Finnish Companies Act, which after the amendment of the Act
and the Company's Articles of Association no longer are necessary,
will be removed. Further, the reference to measures to be taken
pursuant to option rights in the reduction of the share capital was
amended to correspond to the Finnish Companies Act in force.
Furthermore, the terms and conditions were amended so that the
subscription price of the shares both according to the terms and
conditions of the convertible capital loan and the options may be
recognised in the invested free equity fund in its entirety.

The General Meeting authorised the Board of Directors to make other
corresponding amendments to the terms and conditions of the
convertible capital loan and option programmes without changing the
number of shares to be subscribed for pursuant to the convertible
capital loans or option rights or any other material terms and
conditions.

The General Meeting authorised the Board of Directors to resolve on
the issuance of the maximum of 18,000,000 new shares in one or
several instalments in a share issue or on the issuance of options
or other special rights to the shares. The authorisation entitles
the Board of Directors to deviate from the shareholders' pre-emptive
subscription right. The authorisation is effective until 30 June
2008.


PRESIDENT AND CEO'S REVIEW

Timo Veromaa, President and CEO, discussed the company's operations,
results and future in his review. The presentation is available on
the Company's homepage at www.biotie.com.


Turku, 28 March 2007

Biotie Therapies Corp.


Timo Veromaa
President and CEO


For further information, please contact:

Timo Veromaa, President and CEO, Biotie Therapies Corp.
tel. +358 2 274 8901, e-mail: timo.veromaa@biotie.com

www.biotie.com


Distribution:  Helsinki Stock Exchange
               Main Media